LRRK2 and early-onset autosomal dominant Alzheimer disease: Indeed the potential of lowering tau protein for the treatment of Alzheimer’s disease (AD) and other tauopathies has been demonstrated recently [4], as well as targeting alpha-synuclein (SNCA) [5] and leucine-rich-repeat kinase 2 (LRRK2) [6] for Parkinson’s disease (PD), and ataxin-2 for the treatment of spinocerebellar ataxia type 2 (SCA2) [7], sporadic ALS and frontotemporal dementia (FTD) [8].